Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gil Harari

Showing results (11-20 of 36) with videos related to

Pageof 4
Sort By:
European Journal of Internal Medicine|November 7, 2021
Humoral SARS-COV-2 IgG decay within 6 months in COVID-19 healthy vaccinees: The need for a booster vaccine dose?Anat Achiron, Mathilda Mandel, Sapir Dreyer-Alster, et al.
Cell Reports Methods|September 26, 2023
Accurate age prediction from blood using a small set of DNA methylation sites and a cohort-based machine learning algorithmMiri Varshavsky, Gil Harari, Benjamin Glaser, et al.
Journal of Clinical Medicine|June 2, 2021
Bodyweight Measures and Lifestyle Habits in Individuals with Multiple Sclerosis and Moderate to Severe DisabilityMoran Livne-Margolin, Itay Tokatly Latzer, Orit Pinhas-Hamiel, et al.
Journal of Neuroimmunology|September 26, 2022
Cladribine treatment for highly active multiple sclerosis: Real-world clinical outcomes for years 3 and 4David Magalashvili, Mathilda Mandel, Sapir Dreyer-Alster, et al.
European Neurology|January 3, 2023
Radiological Disease Activity in Secondary Progressive Multiple SclerosisDaniela Noa Zohar, David Magalashvili, Sapir Dreyer-Alster, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 28, 2025
Positive impact of cladribine tablets on reducing brain atrophy in patients with relapsing-remitting multiple sclerosis: A longitudinal studyAnat Achiron, Yehuda Warszawer, Yael Nissan, et al.
Clinical Interventions in Aging|June 28, 2014
Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: a 6-month, randomized, placebo-controlled, multicenter trialAlan G Wade, Mildred Farmer, Gil Harari, et al.
Chemical Science|November 7, 2025
Correction: Molecular Aharonov-Bohm-type interferometers based on porphyrin nanoringsChi Y Cheng, Gil Harari, Igor Rončević, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 2, 2018
Residual disability after severe relapse in people with multiple sclerosis treated with disease-modifying therapyAnat Achiron, Ida Sarova-Pinhas, David Magalashvili, et al.
Chemical Science|February 7, 2025
Molecular Aharonov-Bohm-type interferometers based on porphyrin nanoringsChi Y Cheng, Gil Harari, Igor Rončević, et al.
Pageof 4

Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
European Journal of Internal Medicine|November 7, 2021
Humoral SARS-COV-2 IgG decay within 6 months in COVID-19 healthy vaccinees: The need for a booster vaccine dose?Anat Achiron, Mathilda Mandel, Sapir Dreyer-Alster, et al.
Cell Reports Methods|September 26, 2023
Accurate age prediction from blood using a small set of DNA methylation sites and a cohort-based machine learning algorithmMiri Varshavsky, Gil Harari, Benjamin Glaser, et al.
Journal of Clinical Medicine|June 2, 2021
Bodyweight Measures and Lifestyle Habits in Individuals with Multiple Sclerosis and Moderate to Severe DisabilityMoran Livne-Margolin, Itay Tokatly Latzer, Orit Pinhas-Hamiel, et al.
Journal of Neuroimmunology|September 26, 2022
Cladribine treatment for highly active multiple sclerosis: Real-world clinical outcomes for years 3 and 4David Magalashvili, Mathilda Mandel, Sapir Dreyer-Alster, et al.
European Neurology|January 3, 2023
Radiological Disease Activity in Secondary Progressive Multiple SclerosisDaniela Noa Zohar, David Magalashvili, Sapir Dreyer-Alster, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 28, 2025
Positive impact of cladribine tablets on reducing brain atrophy in patients with relapsing-remitting multiple sclerosis: A longitudinal studyAnat Achiron, Yehuda Warszawer, Yael Nissan, et al.
Clinical Interventions in Aging|June 28, 2014
Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: a 6-month, randomized, placebo-controlled, multicenter trialAlan G Wade, Mildred Farmer, Gil Harari, et al.
Chemical Science|November 7, 2025
Correction: Molecular Aharonov-Bohm-type interferometers based on porphyrin nanoringsChi Y Cheng, Gil Harari, Igor Rončević, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 2, 2018
Residual disability after severe relapse in people with multiple sclerosis treated with disease-modifying therapyAnat Achiron, Ida Sarova-Pinhas, David Magalashvili, et al.
Chemical Science|February 7, 2025
Molecular Aharonov-Bohm-type interferometers based on porphyrin nanoringsChi Y Cheng, Gil Harari, Igor Rončević, et al.
Pageof 4